Moderna receives fda emergency use authorization for omicron-targeting bivalent covid-19 booster vaccine in children 6 months through 5 years of age

Mrna-1273.222 targets the ba.4/ba.5 strains of omicron variant authorization is based upon clinical and pre-clinical data for moderna's bivalent vaccines cambridge, ma / accesswire / december 8, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced it has received emergency use authorization (eua) from the u.s. food and drug administration (fda) for its ba.4/ba.5 omicron-targeting bivalent covid-19 booster vaccine, mrna-1273.222, in children 6 months through 5 years of age. the authorization is based on a 10 Μg booster dose following a completed primary series of moderna's original vaccine.
MRNA Ratings Summary
MRNA Quant Ranking